PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Goserelin — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Goserelin is a GnRH agonist analogue that reduces testosterone secretion; in a randomized trial in 415 men with locally advanced prostate cancer, adding three years of goserelin to radiotherapy raised five-year survival from 62% to 79%. · pmid:9233866

In premenopausal women receiving chemotherapy for hormone-receptor-negative breast cancer, adding goserelin lowered ovarian failure at two years (8% against 22%) and more of them later became pregnant. · pmid:25738668

Identity

PubChem CID 5311128: Goserelin, C59H84N18O14, 1269.4 g/mol. · pubchem:5311128

CAS registry number 65807-02-5. · pubchem:5311128

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Goserelin standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. (1997) · establishedGoserelin for ovarian protection during breast-cancer adjuvant chemotherapy. (2015) · established19972015

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Goserelin yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. · pmid 25738668 · 2015
    • Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. · pmid 9233866 · 1997
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.